Clinical Trials
10 trialsNCT05064059 2026-05-26
MK-4280A-007
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT05198934 2026-04-27
CodeBreak300
Amgen
Phase 3 Completed
NCT04776148 2026-02-05
MK-7902-017
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04457297 2026-01-21
ALTAIR
National Cancer Center Hospital East
Phase 3 Completed
NCT05600309 2025-11-26
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04737187 2024-09-24
SUNLIGHT
Taiho Oncology, Inc.
Phase 3 Completed
NCT01607957 2024-09-19
RECOURSE
Taiho Oncology, Inc.
Phase 3 Completed
NCT02500043 2024-09-03
Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer
Taiho Oncology, Inc.
Phase 3 Completed
NCT03520946 2024-08-09
RAMTAS
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 3 Completed
NCT01955837 2020-11-17
TERRA
Taiho Pharmaceutical Co., Ltd.
Phase 3 Completed